IP Library Granted Patent US 9,724,351
Granted Patent B2
US 9,724,351 · App. 14/422,920 · Granted Aug 8, 2017

Compounds for the treatment of paramoxyvirus viral infections

Inventors: Guangyi Wang (Carlsbad, CA); Leonid Beigelman (San Mateo, CA); Anh Truong (Burlingame, CA); Carmela Napolitano (Verona, IT); Daniele Andreotti (Verona, IT); Haiying He (Shanghai, CN)
Assignee: Alios BioPharma, Inc.
A61K31/5377A61K31/381A61K31/404A61K31/407A61K31/4155A61K31/4164A61K31/426A61K31/444A61K31/4418A61K31/4436A61K31/4439A61K31/496A61K31/497A61K31/501A61K31/506A61K45/06C07C243/34C07C251/80C07C251/84C07C255/34C07D207/335C07D209/08C07D209/14C07D209/20C07D209/86C07D213/42C07D213/50C07D213/65C07D213/68C07D215/12C07D215/14C07D215/42C07D217/24C07D233/38C07D233/60C07D233/61C07D233/64C07D233/88C07D261/20C07D277/56C07D277/64C07D307/52C07D307/81C07D311/68C07D333/16C07D333/20C07D333/50C07D333/54C07D333/58C07D333/62C07D333/66C07D333/68C07D335/06C07D401/04C07D401/10C07D401/12C07D405/04C07D405/12C07D409/04C07D409/06C07D409/12C07D409/14C07D413/04C07D413/12C07D417/04C07D417/12C07D471/04C07D495/04C07D495/14C07C2102/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,724,351
App. No.
14/422,920
Granted
Aug 8, 2017
Kind
B2
Abstract

Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).

Claims (32)

1. A compound of Formula (Id), or a pharmaceutically acceptable salt thereof, having the structure:

wherein:

A is selected from the group consisting of an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted aryl and an optionally substituted aryl(C 1-2 alkyl);

Y is an optionally substituted benzothiophene;

R 1 is hydrogen or an unsubstituted C 1-4 alkyl;

R 2 and R 2a1 are each independently selected from the group consisting of hydrogen, an optionally substituted C 1-4 alkyl, alkoxyalkyl, aminoalkyl, hydroxyalkyl, hydroxy and an optionally substituted aryl(C 1-6 alkyl);

R 9a , R 10a and R 11a are each independently selected from the group consisting of hydrogen, halogen, hydroxy, an optionally substituted C 1-8 alkyl, an optionally substituted C 2-8 alkenyl, an optionally substituted C 2-8 alkynyl, an optionally substituted C 3-6 cycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, an optionally substituted hydroxyalkyl, an optionally substituted C 1-8 alkoxy, an optionally substituted alkoxyalkyl, amino, a mono-substituted amino, a di-substituted amino, halo(C 1-8 alkyl), haloalkyl and an optionally substituted C-carboxy; and

wherein, when a group is substituted, the group is substituted with one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, acylalkyl, alkoxyalkyl, aminoalkyl, amino acid, aryl, heteroaryl, heterocyclyl, aryl(alkyl), heteroaryl(alkyl), heterocyclyl(alkyl), hydroxyalkyl, acyl, cyano, hydroxy, halogen, thiocarbonyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, C-carboxy, O-carboxy, isocyanato, thiocyanato, isothiocyanato, azido, nitro, silyl, sulfenyl, sulfinyl, sulfonyl, haloalkyl, haloalkoxy, trihalomethanesulfonyl, trihalomethanesulfonamido, an amino, a mono-substituted amino group and a di-substituted amino group.

2. The compound of claim 1 , wherein R 1 is hydrogen.

3. The compound of claim 1 , wherein R 1 is an unsubstituted C 1-4 alkyl.

4. The compound of claim 1 , wherein both R 2 and R 2a1 are hydrogen.

5. The compound of claim 1 , wherein R 2 is hydrogen and R 2a1 is a substituted or an unsubstituted C 1-4 alkyl, an optionally substituted aryl(C 1-6 alkyl), an alkoxyalkyl, an aminoalkyl, a hydroxyalkyl or hydroxy.

6. The compound of claim 1 , wherein: R 9a , R 10a and R 11a are each independently selected from the group consisting of hydrogen and C 1-8 alkoxy.

7. The compound of claim 1 , wherein A is an optionally substituted aryl.

8. The compound of claim 7 , wherein A is an optionally substituted phenyl.

9. The compound of claim 1 , wherein A is an optionally substituted cycloalkyl or an optionally substituted cycloalkenyl.

10. The compound of claim 1 , wherein Y is an optionally substituted

11. The compound of claim 1 , wherein Y is benzothiophene substituted with one or more R B , wherein each R B is independently selected from the group consisting of: cyano, halogen, an optionally substituted C 1-4 alkyl, an unsubstituted C 2-4 alkenyl, an unsubstituted C 2-4 alkynyl, an optionally substituted aryl, an optionally substituted 5 or 6 membered heteroaryl, an optionally substituted 5 or 6 membered heterocyclyl, hydroxy, C 1-4 alkoxy, alkoxyalkyl, C 1-4 haloalkyl, haloalkoxy, an unsubstituted acyl, an optionally substituted —C-carboxy, an optionally substituted —C-amido, sulfonyl, carbonyl, amino, a mono-substituted amine, a di-substituted amine and

12. The compound of claim 1 , wherein the compound is selected from the group consisting of:

or a pharmaceutically acceptable salt of any of the foregoing.

13. A pharmaceutical composition comprising an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, excipient, or combination thereof.

14. The compound of claim 1 , wherein at least one of R 9a , R 10a and R 11a is a C 1-4 alkoxy.

15. The compound of claim 1 , wherein R 9a is selected from the group consisting of hydrogen, hydroxy, an optionally substituted C 1-8 alkyl, an optionally substituted C 1-8 alkoxy, an optionally substituted alkoxyalkyl, a mono-substituted amino and a di-substituted amino.

16. The compound of claim 1 , wherein R 10a is selected from the group consisting of hydrogen, hydroxy, halogen, an optionally substituted C 1-8 alkyl, an optionally substituted C 2-8 alkenyl, an optionally substituted C 2-8 alkynyl, an optionally substituted C 3-6 cycloalkyl, an optionally substituted aryl, an optionally substituted hydroxyalkyl, an optionally substituted C 1-8 alkoxy, a mono-substituted amino, a di-substituted amino, halo(C 1-8 alkyl) and an optionally substituted C-carboxy.

17. The compound of claim 1 , wherein R 11a is selected from the group consisting of hydrogen, hydroxy and an optionally substituted C 1-8 alkoxy.

18. The compound of claim 8 , wherein A is a di-substituted phenyl.

19. The compound of claim 1 , wherein A is substituted with one or more R A groups selected from the group consisting of an optionally substituted C 1-4 alkyl, cycloalkyl, hydroxy, an optionally substituted C 1-4 alkoxy, halogen, haloalkyl, an optionally substituted haloalkoxy, nitro, amino, a mono-substituted amine, a di-substituted amine, sulfenyl, alkyoxyalkyl, aryl, mono-cyclic heteroaryl, mono-cyclic heterocyclyl and aminoalkyl.

20. The compound of claim 1 , wherein A is substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, phenoxy, bromo, chloro, fluoro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, N,N-di-methyl-amine, N,N-di-ethyl-amine, N-methyl-N-ethyl-amine, N-methyl-amino, N-ethyl-amino, amino, alkylthio, phenyl, imidazole, morpholinyl, pyrazole, pyrrolidinyl, pyridinyl, piperidinyl, pyrrolidinone, pyrimidine, pyrazine, 1,2,4-oxadiazole, —(CH 2 ) 1-2 —NH(CH 3 ), —O(CH 2 ) 2 —NH 2 , —O(CH 2 ) 2 —NH(CH 3 ), —O(CH 2 ) 2 —N(CH 3 ) 2 , —O—(CH 2 ) 2-4 OH, —O(CH 2 ) 2 OCH 3 , —O(CH 2 ) 1-2 -morpholinyl, —O(CH 2 ) 1-2 -triazole, —O(CH 2 ) 1,2 -imidazole,

21. The compound of claim 20 , wherein A is substituted with one or more substituents selected from the group consisting of methyl, hydroxy, methoxy, ethoxy, chloro, fluoro, trifluoromethyl, difluoromethoxy, N,N-di-methyl-amine, N,N-di-ethyl-amine, imidazole, pyrazole, pyridinyl, pyrrolidinone, pyrimidine, 1,2,4-oxadiazole, —O(CH 2 ) 2 —NH 2 , —O(CH 2 ) 2 —NH(CH 3 ), —O(CH 2 ) 2 —N(CH 3 ) 2 , —O—(CH 2 ) 2-4 OH, —O(CH 2 ) 2 OCH 3 , —O(CH 2 ) 1-2 -morpholinyl, —O(CH 2 ) 1-2 -triazole, —O(CH 2 ) 1-2 -imidazole,

22. The compound of claim 1 , wherein Y is substituted by one or more substituents selected from the group consisting of halogen, carbonyl, C 1-4 alkyl, hydroxy, C 1-4 alkoxy, NH 2 and a mono-substituted amine.

23. The compound of claim 1 , wherein Y substituted by one or more halogens.

24. The compound of claim 20 , wherein Y is

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 12, 2022
From: JANSSEN BIOPHARMA, LLC
To: JANSSEN PHARMACEUTICA NV
Reel/Frame 060020/0662 →
CHANGE OF NAME Recorded Dec 20, 2019
From: ALIOS BIOPHARMA, INC.
To: JANSSEN BIOPHARMA, INC.
Reel/Frame 051398/0985 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 20, 2015
From: WANG, GUANGYI; BEIGELMAN, LEONID; TRUONG, ANH; NAPOLITANO, CARMELA; ANDREOTTI, DANIELE; HE, HAIYING
To: ALIOS BIOPHARMA, INC.
Reel/Frame 034999/0451 →
Continuity (3)
Provisional Application 61702646 · Sep 18, 2012
Provisional Application 61692595 · Aug 23, 2012
Related Publication 20150238498A1 · Aug 27, 2015